By rehabilitating donor organs deemed unfit for transplant,
the xenogeneic cross-circulation platform holds potential to
eliminate transplant waitlist mortality.
NEW
YORK, May 8, 2024 /PRNewswire/ -- Xylyx Bio, a
regenerative medicine company developing innovative solutions for
tissue and organ repair, today announced entry into an exclusive
license agreement with Vanderbilt
University for the rights to a xenogeneic cross-circulation
platform that restores damaged donor organs to transplant
condition.
The donor organ shortage remains dire: Every 8 minutes another
person is added to the U.S. transplant waitlist, and 17 people die
each day waiting to receive an organ. Despite this pressing need,
the majority of donor organs are not utilized for transplant, often
due to acute reversible conditions. Salvaging rehabilitated donor
organs can significantly increase the number of organs available
for transplantation.
"Our technology provides the systemic physiologic support and
homeostatic regulation needed to rehabilitate and salvage donor
organs that are not being utilized for transplant. Our team has
demonstrated successful rehabilitation of donor lungs and livers,
and we are thrilled to accelerate the path to patients," said
Matthew Bacchetta, MD, MBA, FACS,
Professor of Cardiac and Thoracic Surgery and Biomedical
Engineering, Director of the Laboratory for Organ Regeneration,
Recovery, and Replacement, and Medical Director of Lung Transplant
at Vanderbilt University Medical
Center.
"This platform represents a breakthrough in the organ transplant
field and is a key addition to Xylyx Bio's portfolio of
regenerative technologies," said Andrea
Nye, President and CEO of Xylyx Bio. "We are proud to
collaborate with Dr. Bacchetta and Vanderbilt
University and are committed to our shared mission to
advance the development of this groundbreaking technology for those
awaiting a life-saving donor organ."
About Xylyx Bio: Xylyx Bio is a
regenerative medicine company developing innovative approaches for
tissue repair and regeneration. Xylyx Bio's mission is to
eliminate transplant waitlist mortality. Robust pipeline
development of Xylyx Bio's organ rehabilitation platform includes
lead programs for donor lungs and donor livers and
pre-clinical programs for kidneys and hearts. To learn more, visit
xylyxbio.com.
About Vanderbilt
University: Vanderbilt
University is globally renowned for its transformative
education and research. Vanderbilt
University Medical Center is the largest comprehensive
research, teaching, and patient care health system in the Mid-South
region, with the highest-ranked adult and children's hospitals in
the Southeast by U.S. News & World Report.
Contact
Andrea Nye
Xylyx Bio, Inc.
andrea@xylyxbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/xylyx-bio-announces-exclusive-license-agreement-with-vanderbilt-university-for-donor-organ-rehabilitation-asset-302139198.html
SOURCE Xylyx Bio, Inc.